These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 8843206)
1. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. Coombs RW; Welles SL; Hooper C; Reichelderfer PS; D'Aquila RT; Japour AJ; Johnson VA; Kuritzkes DR; Richman DD; Kwok S; Todd J; Jackson JB; DeGruttola V; Crumpacker CS; Kahn J J Infect Dis; 1996 Oct; 174(4):704-12. PubMed ID: 8843206 [TBL] [Abstract][Full Text] [Related]
2. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Hughes MD; Johnson VA; Hirsch MS; Bremer JW; Elbeik T; Erice A; Kuritzkes DR; Scott WA; Spector SA; Basgoz N; Fischl MA; D'Aquila RT Ann Intern Med; 1997 Jun; 126(12):929-38. PubMed ID: 9182469 [TBL] [Abstract][Full Text] [Related]
3. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. D'Aquila RT; Johnson VA; Welles SL; Japour AJ; Kuritzkes DR; DeGruttola V; Reichelderfer PS; Coombs RW; Crumpacker CS; Kahn JO; Richman DD Ann Intern Med; 1995 Mar; 122(6):401-8. PubMed ID: 7856987 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. Welles SL; Jackson JB; Yen-Lieberman B; Demeter L; Japour AJ; Smeaton LM; Johnson VA; Kuritzkes DR; D'Aquila RT; Reichelderfer PA; Richman DD; Reichman R; Fischl M; Dolin R; Coombs RW; Kahn JO; McLaren C; Todd J; Kwok S; Crumpacker CS J Infect Dis; 1996 Oct; 174(4):696-703. PubMed ID: 8843205 [TBL] [Abstract][Full Text] [Related]
5. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. O'Brien WA; Hartigan PM; Daar ES; Simberkoff MS; Hamilton JD Ann Intern Med; 1997 Jun; 126(12):939-45. PubMed ID: 9182470 [TBL] [Abstract][Full Text] [Related]
6. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. O'Brien WA; Hartigan PM; Martin D; Esinhart J; Hill A; Benoit S; Rubin M; Simberkoff MS; Hamilton JD N Engl J Med; 1996 Feb; 334(7):426-31. PubMed ID: 8552144 [TBL] [Abstract][Full Text] [Related]
7. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. Japour AJ; Welles S; D'Aquila RT; Johnson VA; Richman DD; Coombs RW; Reichelderfer PS; Kahn JO; Crumpacker CS; Kuritzkes DR J Infect Dis; 1995 May; 171(5):1172-9. PubMed ID: 7538548 [TBL] [Abstract][Full Text] [Related]
8. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine. Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales MA; Sirera G; Clotet B Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824 [TBL] [Abstract][Full Text] [Related]
9. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection. Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. Tierney C; Lathey JL; Christopherson C; Bettendorf DM; D'Aquila RT; Hammer SM; Katzenstein DA J Infect Dis; 2003 Jan; 187(1):144-8. PubMed ID: 12508159 [TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group. AIDS Res Hum Retroviruses; 2000 Aug; 16(12):1123-33. PubMed ID: 10954887 [TBL] [Abstract][Full Text] [Related]
12. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. Sterling TR; Vlahov D; Astemborski J; Hoover DR; Margolick JB; Quinn TC N Engl J Med; 2001 Mar; 344(10):720-5. PubMed ID: 11236775 [TBL] [Abstract][Full Text] [Related]
13. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227 [TBL] [Abstract][Full Text] [Related]
14. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Sperling RS; Shapiro DE; Coombs RW; Todd JA; Herman SA; McSherry GD; O'Sullivan MJ; Van Dyke RB; Jimenez E; Rouzioux C; Flynn PM; Sullivan JL N Engl J Med; 1996 Nov; 335(22):1621-9. PubMed ID: 8965861 [TBL] [Abstract][Full Text] [Related]
15. Emergence of syncytium-inducing human immunodeficiency virus type 1 variants coincides with a transient increase in viral RNA level and is an independent predictor for progression to AIDS. Spijkerman I; de Wolf F; Langendam M; Schuitemaker H; Coutinho R J Infect Dis; 1998 Aug; 178(2):397-403. PubMed ID: 9697719 [TBL] [Abstract][Full Text] [Related]
17. ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team. Para MF; Meehan P; Holden-Wiltse J; Fischl M; Morse G; Shafer R; Demeter LM; Wood K; Nevin T; Virani-Ketter N; Freimuth WW Antimicrob Agents Chemother; 1999 Jun; 43(6):1373-8. PubMed ID: 10348755 [TBL] [Abstract][Full Text] [Related]
18. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors. Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ; Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040 [TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. Cao Y; Ho DD; Todd J; Kokka R; Urdea M; Lifson JD; Piatak M; Chen S; Hahn BH; Saag MS AIDS Res Hum Retroviruses; 1995 Mar; 11(3):353-61. PubMed ID: 7786581 [TBL] [Abstract][Full Text] [Related]
20. Predicting HIV disease progression in children using measures of neuropsychological and neurological functioning. Pediatric AIDS clinical trials 152 study team. Pearson DA; McGrath NM; Nozyce M; Nichols SL; Raskino C; Brouwers P; Lifschitz MC; Baker CJ; Englund JA Pediatrics; 2000 Dec; 106(6):E76. PubMed ID: 11099619 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]